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Background: Acute pancreatitis is the most common serious complication of
endoscopic retrograde cholangiopancreatography (ERCP). Although, somatostatin
(SOM) has been used in the prevention of post-ERCP pancreatitis (PEP), the efficacy
of SOM remains inconsistent.
Methods: Electronic databases, including PubMed/MEDLINE, EMBASE, the Cochrane
Central Register of Controlled Trials (CENTRAL, The Cochrane Library), and the Science
Citation Index were searched to retrieve relevant studies. Details of the study population,
including patients’ characteristics, sample size, regimen of drug administration and
incidence of PEP, hyperamylasemia and abdominal pain were extracted by two
investigators. Data were analyzed with Review Manager 5.3 software.
Results: Eleven randomized controlled trials, enrolling a total of 4192 patients, were
included in the meta-analysis. After data were pooled, we observed decreased
incidence of ERCP-induced outcomes, such as PEP (RR = 0.63, 95% CI: 0.40, 0.98;
P = 0.04) and hyperamylasemia (RR = 0.75, 95% CI: 0.66, 0.84; P < 0.001) in
patients treated with SOM than those with placebo. Subgroup analysis by ethnicity
found decreased incidence of PEP and hyperamylasemia in Asia only. Subgroup
analysis by treatment schedule and dosage revealed decreased incidence of PEP and
hyperamylasemia when SOM were treated with a single bolus or long-term infusion, or
at dose above 3000 µg. We did not observed efficacy of SOM on abdominal pain in
pooled or subgroup analysis.
Conclusion: This meta-analysis of patients undergoing ERCP showed reduced
incidence of PEP and hyperamylasemia when SOM was administrated with single bolus,
long-term infusion, or high dosage. More data are needed to confirm our findings.
Keywords: somatostatin, endoscopic retrograde cholangiopancreatography, pancreatitis, hyperamylasemia,
meta-analysis
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INTRODUCTION
Acute pancreatitis is the most common serious complication
of endoscopic retrograde cholangiopancreatography (ERCP)
that has been associated with high morbidity and mortality
(Freeman and Guda, 2004). It occurs in 2–9% general
population and 15% in high-risk patients (Cheng et al., 2006).
Although, mild post-ERCP pancreatitis (PEP) generally has few
complications with optimal outcome, severe PEP can lead to
serious complications, such as systemic inflammatory response,
pseudocysts or pancreatic necrosis and even death in a significant
portion of patients. In the last three decades, extensive studies
were made to investigate the solutions of reducing associated risk
and increasing the safety (Choudhary et al., 2011; Dumonceau
et al., 2014; Luo et al., 2016). It has demonstrated that the major
therapy for PEP is pharmaco-prevention with different agents,
such as somatostatin (SOM), non-steroidal anti-inflammatory
drugs (NSAIDs), and indomethacin (Kubiliun et al., 2015).
Somatostatin, a potent inhibitor of pancreatic exocrine
function, has been found to prevent or mitigate the processes of
pancreatic inflammation. However, the efficacy is not consistent
when SOM was used at different doses and duration schedules.
Rudin et al. (2007) found that SOM administered as a bolus
could reduce the incidence of ERCP-induced complications,
such as PEP and hyperamylasemia. Consistently, a meta-analysis
reported decreased risk of PEP in patients receiving high-dose
SOM over 12 h (Omata et al., 2010). A recent meta-analysis
further demonstrated decreased incidence of PEP at a single
bolus or long-term injection, but no decreased incidence when
given as short-term infusion, but (Qin et al., 2015). Therefore,
further investigation is required to uncover appropriate methods
of administration of SOM to prevent PEP.
In this study, we aim to reassess the effects of SOM on
ERCP-induced complications, including PEP, hyperamylasemia
and abdominal pain using a meta-analytic approach. We also
performed subgroup analyses according to ethnicity, treatment
schedule, and dosage to investigate the rational application of
SOM for improved benefits.
MATERIALS AND METHODS
Literature Search
Literature search was conducted according to the PRISMA
statement developed specifically for meta-analyses to improve
the reporting of reviews (Moher et al., 2009). The following
databases were searched from their inception through July 2016:
PubMed/MEDLINE, EMBASE, the Cochrane Central Register
of Controlled Trials (CENTRAL, The Cochrane Library), and
the Science Citation Index. Search strategy was performed with
both free-text terms and MeSH terms, including “pancreatitis,”
“ERCP,” and “somatostatin.” There is no requirement on
publication date or type of studies.
Study Selection
Two investigators (Pei-Lin Li, Tao Zhang) independently
reviewed titles and abstracts for relevance. All articles assessed
as relevant were included for full-text review. The criteria for
inclusion were: (1) randomized controlled trials (RCTs), (2)
reporting at least two outcomes, (3) only the most recent study
was included if more than one study was published using the
same study population. Open or uncontrolled clinical trials,
observational studies and case reports were excluded from the
meta-analysis.
Data Extraction and Quality Assessment
Two investigators (Tao Zhang, Jin-Ping Chen) independently
extracted details of the study population, including patients’
characteristics, sample size, regimen of drug administration and
incidence of PEP, hyperamylasemia and abdominal pain. The
Jadad score is used to assess the methodological quality of
selected studies (Jadad et al., 1996). Assessment discrepancies
were resolved by discussion with by Dr. Jing Hu until consensus
was reached.
Data Analysis
Meta-analyses were conducted using Review Manager 5.3
(Cochrane Collaboration, Oxford, UK). Dichotomous data, such
as incidence of PEP, hyperamylasemia and abdominal pain, were
expressed as relative risk (RR) with 95% confidence interval (CI).
Heterogeneity was quantified with Cochran’s Q test. When there
was considerable heterogeneity (P ≥ 0.10 and I2 ≤ 50%), the
data were analyzed in a fixed-effects model. When there was low
heterogeneity (I2 > 50% or P < 0.10), the data were analyzed in
a fixed-effects mode. A funnel plot was used to assess potential
publication bias.
RESULTS
Identification of Eligible Studies
As shown in Figure 1, a total of 543 articles were identified and
146 were remained after removal of duplications. 119 articles
were excluded: 87 articles due to non-relevance, 18 non-RCT
articles, and 14 articles unable to retrieve. In total, 27 articles
were reviewed in detail, of which 16 were excluded due to non-
relevance. Finally, 11 eligible studies satisfied the criteria for our
meta-analysis.
Characteristics of Included Studies
The baseline characteristics of the 11 studies published between
1998 to 2015 are presented in Supplementary Table S1 (Bordas
et al., 1998; Poon et al., 1999; Andriulli et al., 2002, 2004; Poon
et al., 2003; Arvanitidis et al., 2004; Chan et al., 2008; Lee et al.,
2008; Wang et al., 2013; Concepción-Martín et al., 2014; Bai et al.,
2015). Totally, 4192 patients undergo ERCP procedures above
average age of 58 years were analyzed. The Jaded score for 11
RCTs were ≥4, suggesting their high quality. Table 1 lists the
intervention of SOM and post-ERCP complications.
Incidence of PEP
PEP occurred in 117 (5.44%) out of 2,152 patients treated
with SOM, and 159 (7.79%) out of 2,040 patients treated with
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FIGURE 1 | Flow diagram of eligible articles selection process.
TABLE 1 | Intervention in 11 RCTs.
Study (years) Treatment style of SOM Dosage Starting time of therapy Duration Outcome measures
Bordas et al., 1998 Intravenous injection 4 µg/kg On identification of papilla Bolus IPEP
Poon et al., 1999 Intravenous injection 3000 µg 30 min before ERCP 12 h IPEP, H, AP
Andriulli et al., 2002 Intravenous injection 750 µg 30 min before ERCP 2.5 h IPEP, H, AP
Poon et al., 2003 Intravenous injection 250 µg Immediately after diagnostic ERCP Bolus IPEP, H, AP
Andriulli et al., 2004 Intravenous injection 750 µg 30 min before ERCP 6.5 h IPEP, H, AP
Arvanitidis et al., 2004 Intravenous injection 4 µg/kg 1 h before ERCP Bolus IPEP, H
3000 µg 12 h
Chan et al., 2008 Intravenous injection 250 µg/h Before ERCP Bolus plus 12 h IPEP, H
250 µg Bolus
Lee et al., 2008 Intravenous injection 3000 µg 30 min before ERCP 12 h IPEP, H
Wang et al., 2013 Intravenous injection 250 µg/h 1 h before ERCP 24 h IPEP, H
250 µg/h 1 h after ERCP
Concepción-Martín et al., 2014 Intravenous injection 1250 µg Before cannulation of papilla Bolus plus 4 h IPEP, H, AP
Bai et al., 2015 Intravenous injection 3000 µg Before ERCP Bolus plus 11 h IPEP, H
SOM, somatostatin; ERCP, endoscopic retrograde cholangiopancreatography; IPEP, incidence of post-ERCP pancreatitis; H, hyperamylasemia; AP, abdominal pain.
placebo (Supplementary Figure S1). The random-effect model
demonstrated significantly decreased PEP risk in patients treated
with SOM (RR= 0.63, 95% CI: 0.40, 0.98; P = 0.04).
We then performed subgroup analysis according to area,
treatment schedule and dosage. In five RCTS in Europe, PEP
incidence is comparable in patients treated with SOM (6.16%)
and placebo (6.56%) (RR = 0.77, 95% CI: 0.37, 1.61; P = 0.49)
(Figure 2A). In six RCTs in Asia, we found significantly
decreased risk of PEP incidence when patients were treated
with SOM (RR = 0.48, 95% CI: 0.34, 0.69; P < 0.001)
(Figure 2B).
Figure 3 shows RR in subgroup analysis according to doses
and duration schedules of SOM. PEP risk is decreased in patients
receiving SOM with a single bolus than placebo (2.95% vs.
10.36%) (RR = 0.28, 95% CI: 0.15, 0.54; P < 0.001) (Figure 3A).
When SOM was administrated as short-term infusion, the
incidence of PEP showed marginal decrease than placebo (8.05%
vs. 5.39%) (R = 1.49, 95% CI: 0.96, 2.32; P = 0.08) (Figure 3B).
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FIGURE 2 | Forest plot of RR of PEP in Europe (A) and Asia (B). I2 and P is the criterion of heterogeneity test,  pooled RR, —— RR and 95% CI.
We observed significantly decreased PEP risk when SOM was
administrated as long-term infusion (RR = 0.39, 95% CI: 0.24,
0.65; P < 0.001) (Figure 3C). However, when SOM was treated
as bolus plus continuous infusion, the incidence was comparable
between SOM and placebo (5.38% vs. 6.98%) (RR= 0.77, 95% CI:
0.52, 1.14; P = 0.20) (Figure 3D).
Subgroup analysis according to dose shows decreased
incidence of PEP in patients treated with SOM at ≥3000 µg
(4.44% vs. 8.61%) (RR = 0.48, 95% CI: 0.33, 0.69; P < 0.0001)
(Figure 4A). However, when SOM dose decreased to less than
3000 µg, there is no significant difference in PEP risk (RR= 0.71,
95% CI: 0.38, 1.33; P = 0.28) (Figure 4B).
Hyperamylasemia
Hyperamylasemia was analyzed in 10 studies and in a total of
4,032 patients. Hyperamylasemia occurred in 346 (16.7%) out
of 2,072 patients treated with SOM, and 388 (19.80%) out of
1,960 patients treated with placebo (Supplementary Figure S2).
The fixed-effect model demonstrated significantly decreased risk
of hyperamylasemia (RR= 0.75, 95% CI: 0.66, 0.84; P < 0.001).
Subgroup analysis according to ethnicity shows no difference
in hyperamylasemia incidence in SOM and placebo-treated
patients (17.99% vs. 17.61%) (RR = 0.89, 95% CI: 0.64,
1.23; P = 0.48) in Europe (Figure 5A). The incidence of
hyperamylasemia was decreased in SOM patients (15.44% vs.
20.73%) (RR = 0.48, 95% CI: 0.34, 0.69; P < 0.001) in Asia
(Figure 5B).
Subgroup analysis according to schedules showed decreased
incidence of hyperamylasemia with a single bolus treatment of
SOM compared with placebo (RR = 0.70, 95% CI: 0.57, 0.86;
P < 0.001) (Figure 6A). When SOM was administrated as short-
term infusion, the risk of hyperamylasemia incidence was not
decreased compared with placebo (RR = 0.86, 95% CI: 0.53,
1.41; P = 0.56) (Figure 6B). We observed significantly decreased
hyperamylasemia risk when SOM was administrated as long-
term infusion (RR = 0.69, 95% CI: 0.57, 0.83; P < 0.0001)
(Figure 6C), but no difference when SOM was treated as
bolus plus continuous infusion (RR = 0.84, 95% CI: 0.50, 1.40;
P = 0.51) (Figure 6D).
Subgroup analysis according to dose shows decreased
incidence of hyperamylasemia in patients treated with SOM at
≥3000 µg (16.16% vs. 23.67% ) (RR = 0.67, 95% CI: 0.57,
0.79; P < 0.001) (Figure 7A). When SOM dose decreased to
less than 3000 µg, we found significantly decreased risk of
hyperamylasemia (RR = 0.81, 95% CI: 0.69, 0.96; P = 0.01)
(Figure 7B).
Abdominal Pain
Post-ERCP abdominal pain was reported in 163 (15.78%) out of
1,033 patients treated with SOM, and 168 (15.34%) out of 1,095
patients treated with placebo (Supplementary Figure S3). There is
no significant difference in the risk of abdominal pain (RR= 0.89,
95% CI: 0.62, 1.27; P = 0.52).
Publication Bias
A funnel plot was used to express the publication bias. There were
11 trials included in the funnel plot of incidence of PEP. A little
asymmetry was observed in this funnel plot (Figure 8A). The
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FIGURE 3 | Forest plot of RR of PEP in patients treated with SOM as single bolus (A), short-term infusion (B), long-term infusion (C), and bolus plus
continuous infusion (D). I2 and P is the criterion of heterogeneity test,  pooled risk ratio, —— risk ratio and 95% CI.
funnel plot of hyperamylasemia was also applied. Publication bias
was found in the outcome of hyperamylasemia (Figure 8B).
DISCUSSION
Despite medical condition enormously improved over the
several decades, little progress has been made toward the
goal of founding appropriate agents for preventing PEP
(Kubiliun et al., 2015). SOM was firstly found potential for PEP
in 1980s. However, the efficacy of SOM on PEP seems to be along
with contradictory results based on several properly designed,
well-executed, prospective randomized trials. Therefore, the
opinion on its clinical benefit remains far from consistent. In
recent years, there were mainly six meta-analyses focusing on
the efficacy of SOM. Andriulli reported a meta-analysis of the
preventive efficacy of somatostatin and its analog on PEP in
Andriulli et al. (2000). The analysis concluded that pancreatic
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FIGURE 4 | Forest plot of RR of PEP when SOM was administrated at high (≥3000 µg) (A) and low dose (<3000 µg) (B). I2 and P is the criterion of
heterogeneity test,  pooled risk ratio, —— risk ratio and 95% CI.
FIGURE 5 | Forest plot of RR of ERCP-induced hyperamylasemia in Europe (A) and Asia (B). I2 and P is the criterion of heterogeneity test,  pooled risk
ratio, —— risk ratio and 95% CI.
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FIGURE 6 | Forest plot of RR of ERCP-induced hyperamylasemia in patients treated with SOM as single bolus (A), short-term infusion (B), long-term
infusion (C), and bolus plus continuous infusion (D). I2 and P is the criterion of heterogeneity test,  pooled risk ratio, —— risk ratio and 95% CI.
injury after ERCP could be prevented with the administration
of SOM with an OR of 0.38 (95% CI: 0.22, 0.65; P < 0.001).
Moreover, SOM was also able to reduce hyperamylasemia and
abdominal pain (OR = 0.65, 95% CI: 0.48, 0.90; P = 0.008
and OR = 0.24, 95% CI: 0.14, 0.42; P < 0.001). After 7 years,
Andriulli and Rudin respectively updated the meta-analyses
by including several high-quality trials on SOM. The result
from Andriulli’ research reported that SOM was ineffective in
reducing PEP and pain. Meanwhile, there was limited efficacy
on hyperamylasemia. The significant efficacy of SOM on PEP
was obtained only in the subgroup of patients receiving with
bolus injection (Andriulli et al., 2007). The research from Rudin
also confirmed that SOM can significantly decrease the incidence
of PEP with only long-term infusion or bolus. However, there
was no difference between control and SOM arms with short-
term infusion (Rudin et al., 2007). Further research performed
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FIGURE 7 | Forest plot of RR of ERCP-induced hyperamylasemia SOM was administrated at high (≥3000 µg) (A) and low dose (<3000 µg) (B). I2 and P
is the criterion of heterogeneity test,  pooled risk ratio, —— risk ratio and 95% CI.
FIGURE 8 | Funnel plot for the publication bias. (A) PEP. (B) hyperamylasemia.
by Omata summarized that the preventive efficacy of SOM was
more prominent in cases high-dose administration over 12 h,
or bolus injection (Omata et al., 2010). Kubiliun et al. (2015),
Qin et al. (2015), two meta-analyses further confirmed that
the benefit of SOM has been demonstrated more consistently
with bolus administration than with infusion. Apart from bolus
administration seemed to be the prominent method, the benefits
from other administration methods, duration and dosage of
SOM were inconsistent. In addition, two new clinical trials were
further published from 2014 to 2015. We therefore conducted
this meta-analysis to find out more accurate result of SOM on
PEP.
Eleven high-quality RCTs involving a total of 4192 participants
receiving SOM or placebo during ERCP were included in our
study. The result showed a significant decline in incidence of
PEP and hyperamylasemia based on the pooled data of SOM. It
indicated that SOM might be effective on PEP. Further outcomes
were analyzed to evaluate the preventive efficacy of subgroups
according to area, treatment schedule and dosage. The pooled
data indicated a remarkable decrease of PEP treated with SOM
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in Asia, whereas, there appeared no change between SOM
and placebo treatment in Europe. The hyperamylasemia was
in accordance with the change of PEP. Therefore, SOM might
be more efficient for Asian than European. This is the first
time to demonstrate the relationship between the efficacy of
SOM and area. Moreover, we also explored the four subgroups
according to schedule of treatment such as bolus, short-term
infusion, long-term infusion and bolus plus continuous infusion
to assess its preventive efficacy. SOM demonstrated significant
decline of PEP and hyperamylasemia with both bolus and long-
term infusion. The result is in according with previous study.
Surprisingly, SOM was not effective applied with neither short-
term infusion nor bolus plus continuous infusion. Moreover,
SOM even presented the opposite trend to increase the incidence
of PEP compared with placebo with short-term infusion. Why
could single bolus be effective than short-term infusion? As a
possible explanation, we supposed that single bolus of SOM was
able to achieve the peak at a critical point which enabled SOM
exert its protective efficacy of PEP. This critical point is possibly
the introduction of the catheter to the papilla. On the contrary,
the short-term infusion of SOM failed to yield the peak and
resulted in ineffectiveness. The previous used to pointed out
that there was a significant efficacy of SOM on PEP with high-
dose over 12 h. We further investigated the relationship between
dosage and efficacy. It was confirmed that SOM could decrease
the incidence of PEP at no less than 3000 µg. In addition, SOM
was also proved to be able to reduce hyperamylasemia in our
study.
There are several limitations in our study. Firstly, we
disregarded few non-English-language literatures. This might be
one of the reasons for publication bias in our meta-analyses.
Secondly, due to limited or missing data about subsets in current
trials, there are still several details such as sex, age, reasons for
ERCP and so on were unable to be analyzed in subgroups. Finally,
the promising result of this study still need further confirmation
by the most practical and likely cost-effective approach.
CONCLUSION
The current meta-analytic data on efficacy of SOM on patients
undergoing ERCP varied from area to dosage. It is clear from
our study that the beneficial efficacy of SOM used in Asia was
more likely to reduce the incidence of PEP and hyperamylasemia.
Moreover, when given as a single bolus or long-term injection,
SOM still maintains its role in this field. High dosage of SOM
demonstrated the obvious efficacy than low dose. However, high-
quality clinical trials are still needed to improve the residual
doubts.
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